Surrozen (SRZN) to Release Quarterly Earnings on Monday

Surrozen (NASDAQ:SRZN) is projected to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.2875) per share and revenue of $0.6610 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Surrozen Stock Performance

Shares of NASDAQ:SRZN opened at $25.15 on Monday. Surrozen has a 52-week low of $5.90 and a 52-week high of $29.59. The company has a market capitalization of $215.54 million, a P/E ratio of -1.13 and a beta of 0.53. The company has a 50-day simple moving average of $23.98 and a 200 day simple moving average of $18.58.

Insiders Place Their Bets

In other news, Director Tim Kutzkey acquired 18,052 shares of Surrozen stock in a transaction dated Tuesday, January 20th. The stock was bought at an average price of $19.60 per share, for a total transaction of $353,819.20. Following the completion of the acquisition, the director directly owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. The trade was a 1.81% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Group Gp Lp Column III bought 18,052 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was purchased at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the transaction, the insider directly owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. The trade was a 1.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 208,410 shares of company stock worth $4,466,346 over the last three months. Insiders own 43.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new position in Surrozen during the 4th quarter worth $99,000. Marshall Wace LLP bought a new stake in shares of Surrozen in the fourth quarter valued at about $247,000. Ieq Capital LLC acquired a new position in shares of Surrozen in the fourth quarter valued at about $304,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Surrozen in the fourth quarter valued at about $310,000. Finally, Citadel Advisors LLC increased its position in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the period. 66.57% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SRZN. Cantor Fitzgerald assumed coverage on Surrozen in a research report on Thursday, February 19th. They issued an “overweight” rating and a $40.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.